Even if you are eligible for subsidies to bring down the price of your insurance, it still wont help you obtain access to medications. Whereas the average premium in Michigan will increase 7 percent, the next time Michiganians try to fill a prescription at the pharmacy they may find something worse the insurers they are paying have no obligation to follow their doctors decisions. Patients may also find that insurers are opting to override their doctors suggested prescription in favor of a less expensive treatment option, regardless of its efficacy. This is one of many reasons consumer distrust toward health insurers is growing and rightfully so. Day in and day out the health care conversation is continually directed to drug prices, which is what insurers are hoping Michiganders will focus on, rather than examining a practice that is more dangerous to consumer health. The only person I want making my health care decisions is me, under the guidance of my doctor. The insurer has no place in the examination room. We trust our doctor to be the arbiter of our health and patients want to know when they walk into a doctors office they are going to receive the best available care determined by their physician, not their insurer. Insurer obstruction in medical decisions will only worsen unless lawmakers take action. no data Insurers have conveniently situated themselves in the middle of the sacred physician-patient relationship, altering treatment plans to save money while disregarding the professional opinion of the prescribing doctor.
For the original version including any supplementary images or video, visit http://www.detroitnews.com/story/opinion/2016/11/29/insurers-doctors/94647462/
Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception his comment is here of historical trends, current conditions and expected future developments, as well as the no data factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the advancement of the Company’s transdermal pyridoxine/doxylamine program into a Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for Vistitan ; the timing of the Company’s follow-on, multi-dose bioavailability study for the its transdermal aripiprazole program; and the Company’s expectations regarding the tech transfer to its development partner with respect to the Company’s transdermal patch for clobazam. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the check out the post right here products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/aequus-provides-q3-2016-financial-130000680.html